Uterine leiomyoma Medical Services in China

Uterine leiomyoma—commonly known as uterine fibroids—is a benign monoclonal smooth muscle tumor arising from the myometrium of the uterus. These tumors are estrogen- and progesterone-sensitive, exhibiting growth during reproductive years and typically regressing after menopause. Pathogenically, leiomyomas originate from genetic alterations in myometrial stem cells, with recurrent mutations in the MED12 gene (present in ~70% of cases), HMGA2 rearrangements, and abnormalities in the TGF-β, WNT/β-catenin, and PI3K/AKT/mTOR signaling pathways. Epigenetic dysregulation, extracellular matrix remodeling, and local tissue hypoxia further contribute to tumor initiation and expansion. Epidemiologically, uterine leiomyomas affect approximately 40–80% of women by age 50, with higher prevalence among Black women (up to 80% by age 45), earlier onset, larger size, and greater symptom burden. Risk factors include early menarche (<11 years), nulliparity, obesity (BMI ≥30), hypertension, vitamin D deficiency, family history, and African ancestry. Conversely, parity, oral contraceptive use (especially long-term low-dose formulations), and smoking (though not recommended due to health risks) are associated with reduced risk. Symptomatology varies widely: up to 50% of cases are asymptomatic, while others experience heavy or prolonged menstrual bleeding (menorrhagia), pelvic pressure or pain, urinary frequency or retention, constipation, dyspareunia, and reproductive challenges—including subfertility, recurrent pregnancy loss, and obstetric complications such as placental abruption or preterm birth. Quality of life impact is substantial: chronic anemia from blood loss leads to fatigue and cognitive impairment; pelvic discomfort restricts physical activity and sexual function; and emotional distress—including anxiety, depression, and diminished body image—is prevalent, particularly among younger patients facing fertility concerns. Economic burden extends beyond direct medical costs to lost work productivity and caregiver strain. Early diagnosis via transvaginal ultrasound (TVUS) or MRI is critical for risk stratification and personalized management. Given its hormone-dependent nature and heterogeneous clinical behavior, treatment must be individualized—not solely based on size or number, but on symptom severity, reproductive goals, patient preference, and anatomical location (submucosal, intramural, subserosal, or pedunculated). Multidisciplinary care involving reproductive endocrinologists, interventional radiologists, gynecologic oncologists, and minimally invasive surgeons ensures optimal outcomes in the Department of Reproductive Medicine.

Uterine leiomyomas—commonly termed fibroids—are benign monoclonal smooth muscle tumors of the myometrium, affecting up to 70–80% of women by age 50. While often asymptomatic, they may cause menorrhagia, pelvic pressure or pain, urinary frequency, constipation, subfertility, or recurrent pregnancy loss. Management in the Department of Reproductive Medicine prioritizes fertility preservation, symptom control, and individualized risk-benefit assessment. Treatment strategies are stratified according to symptom severity, tumor size and location (submucosal, intramural, subserosal), reproductive goals, age, comorbidities, and patient preference.

Conservative management is first-line for asymptomatic or minimally symptomatic patients, particularly those approaching menopause or with small, stable fibroids (<5 cm). This entails clinical surveillance with pelvic ultrasound every 6–12 months, hemoglobin monitoring for anemia, and lifestyle counseling—including iron-rich nutrition, regular physical activity, and avoidance of exogenous estrogen sources (e.g., unopposed hormone therapy). In reproductive-age patients desiring conception, conservative observation remains appropriate if fibroids do not distort the endometrial cavity or exceed 4 cm in diameter, as evidence suggests submucosal and large intramural (>5 cm) lesions most adversely impact implantation and live birth rates.

Pharmacotherapy serves both diagnostic and therapeutic roles. Gonadotropin-releasing hormone (GnRH) agonists (e.g., leuprolide) induce temporary hypoestrogenic states, reducing fibroid volume by 30–60% over 3–6 months; however, rebound growth occurs post-discontinuation, limiting long-term use. GnRH antagonists (e.g., elagolix, relugolix) offer more rapid onset and improved tolerability, with combination regimens (e.g., relugolix + estradiol/norethindrone acetate) approved for extended use up to 24 months to control bleeding and anemia while preserving bone mineral density. Selective progesterone receptor modulators (SPRMs), notably ulipristal acetate (though currently restricted in some regions due to hepatic safety concerns) and newer agents like vilaprisan (under investigation), demonstrate potent antiproliferative effects on leiomyoma tissue with minimal systemic hormonal disruption. Tranexamic acid (1.0 g orally three times daily during menses) significantly reduces menstrual blood loss without hormonal effects and is ideal for perimenopausal or contraindicated patients. Combined oral contraceptives or progestin-only methods (e.g., levonorgestrel-releasing intrauterine system [LNG-IUS]) provide effective cycle control and endometrial suppression, though they do not shrink fibroids. Iron supplementation is mandatory for iron-deficiency anemia, with intravenous ferric carboxymaltose preferred for severe deficiency or malabsorption.

Surgical intervention is indicated for refractory symptoms, rapid growth suspicious for malignancy (though <0.1% risk), infertility attributable to cavity distortion, or compressive sequelae. Myomectomy—gold standard for fertility preservation—is performed via hysteroscopic (for submucosal types ≤4 cm), laparoscopic (for intramural/subserosal ≤8–10 cm), or abdominal (for multiple, large, or deeply infiltrating fibroids) approaches. Robotic-assisted laparoscopy enhances dexterity in complex cases, improving suture precision and reducing conversion rates. All modalities require meticulous myometrial repair to minimize uterine rupture risk in subsequent pregnancy. Uterine artery embolization (UAE) offers a minimally invasive alternative with ~85% symptom improvement at 2 years; however, it carries higher risks of ovarian dysfunction, post-embolization syndrome, and reduced ovarian reserve—making it less favorable in young, fertility-seeking patients. Magnetic resonance-guided focused ultrasound surgery (MRgFUS) provides non-invasive ablation under real-time imaging but has limited efficacy for large, posterior, or pedunculated fibroids and is contraindicated with intrauterine devices or extensive calcification.

China’s Reproductive Medicine Departments offer distinct advantages in leiomyoma management. First, integration of traditional Chinese medicine (TCM) with evidence-based Western protocols is routine: standardized herbal formulas (e.g., Guizhi Fuling Wan) are prescribed adjunctively to reduce pelvic congestion and modulate angiogenesis, supported by randomized trials demonstrating synergistic reduction in bleeding and fibroid volume when combined with SPRMs. Second, China leads globally in robotic surgical adoption—over 90% of tier-3 hospitals deploy da Vinci Xi systems, enabling high-volume, low-complication myomectomies with median operative times <120 minutes and hospital stays of 2–3 days. Third, centralized national registries (e.g., China Fibroid Registry) facilitate longitudinal outcome tracking, informing personalized recurrence prediction models incorporating genomic profiling (MED12 mutation status) and MRI texture analysis. Fourth, cost-effectiveness is exceptional: comprehensive myomectomy with advanced imaging and pathology costs <USD 4,500—approximately 40% lower than comparable care in North America or Western Europe—without compromising quality metrics (98% 30-day readmission-free survival, >95% patient satisfaction in national surveys).

Post-treatment recovery emphasizes structured rehabilitation. Patients undergoing hysteroscopic myomectomy resume normal activity within 3–5 days but avoid tampons, intercourse, and swimming for 2 weeks to prevent infection. Laparoscopic/abdominal myomectomy requires 2–4 weeks off work and 6–8 weeks before resuming heavy lifting (>10 kg) or vigorous exercise. All surgical patients receive thromboprophylaxis (enoxaparin 40 mg SC daily × 7 days) and early ambulation protocols. For pharmacologic therapy, monthly liver enzyme and hemoglobin monitoring is mandated during SPRM or GnRH antagonist use. Nutritional guidance includes daily intake of ≥18 mg elemental iron (if anemic), omega-3 fatty acids (to modulate inflammation), and avoidance of ultra-processed foods linked to elevated IGF-1 levels. Fertility counseling begins immediately post-recovery: hysterosalpingography or saline-infusion sonohysterography is recommended 3 months after myomectomy to confirm cavity integrity; embryo transfer is typically deferred until 6 months post-surgery to allow optimal myometrial healing. Long-term surveillance includes annual transvaginal ultrasound and symptom diaries to detect recurrence—occurring in ~15–30% at 5 years—prompting timely re-stratification. Ultimately, successful management hinges on shared decision-making, multidisciplinary coordination (gynecologic oncology, reproductive endocrinology, interventional radiology), and culturally attuned support systems that recognize psychosocial impacts of chronic gynecologic conditions.